Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091732 | 0.98 | TDP1 (0.66) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL4768516 | 0.93 | TDP1 (0.62) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL273379 | 0.85 | CHRNA7 (0.57) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL2845851 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485634 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL725483 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL8658187 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL3048356 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485667 | 0.85 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL23014817 | 0.83 | TDP1 (0.65) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TDP1 4548/4885L3MBTL1 2575/4885HRH1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.